Fulgent Genetics Q2 revenue rises 20% sequentially, sees billing system transition delay
FLGT•Outlook
Fulgent Genetics now expects 2026 revenue in the range of $330.0 million to $340.0 million.
The company sees 2026 non-GAAP loss of $63.0 million to $67.0 million and expects 2026 non-GAAP loss per share of $2.22 to $2.35.
Result drivers
- Billing system transition: The company said delays in processing and collections from the final phase of its revenue cycle management and billing system transition affected results.
- AI and digital pathology: Fulgent said expansion of its AI portfolio and integration of digital pathology tools improved efficiency and quality in its laboratory services business.
Key financial details
| Metric | Actual | Consensus Estimate |
|---|---|---|
| Q2 Revenue | $85.39 mln | $94 mln (1 analyst) |
| Q2 Adjusted EBITDA | -$17.10 mln | -$4 mln (1 analyst) |
| Q2 Gross Profit | $25.68 mln | |
| Q2 Operating Expenses | $61.75 mln | |
| Q2 Operating Income | -$36.07 mln | |
| Q2 Pretax Loss |
